Searched for
TIRZEPATIDE MARKET SHARE
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- After Gurgaon’s Rs 70 lakh fake Mounjaro seizure, more stocks found in Hyderabad; Racket may span multiple statesThe investigation into fake Mounjaro injections has widened beyond NCR after authorities confirmed that part of the seized batch was sent t...
- Social media is abuzz with weight-loss drug retatrutide and longevity goals. What is the drug all about?A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge genericsNovo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments...
- Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market shareNovo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide ...
- Glenmark set to join peers in 'Semaglutide' pushGlenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...
- Eli Lilly sticks to premium pricing for its innovator drug ahead of generics waveEli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...
- Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal against Eli Lilly’s TirzepatideNVO stock today: Novo Nordisk shares plummeted after its next-generation weight loss drug, CagriSema, failed to achieve non-inferiority in ...
- Dr Reddy’s gets nod to make generic semaglutide for weight lossDr Reddy's Laboratories is set to launch generic semaglutide, a popular weight loss drug. An expert committee has approved their proposal. ...
- Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial missLilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...
- Indian generics wave next year set to sink obesity drug priceLeading Indian drugmakers are preparing to launch generic versions of semaglutide by March. Analysts predict a significant price drop, pote...
- ET Graphics: Weight loss drugs Tirzepatide, Semaglutide dominate India, misuse fears riseTirzepatide and semaglutide dominate India's anti-obesity drug market, holding a 75% share. While seen as vital tools by doctors, experts c...
- You can get a shot for speedy weight loss at Rs 14k a monthThe 2.5 mg vial and 5 mg vial will be available at Rs 3,500 and Rs 4,375, respectively. A spokesperson said as Mounjaro (tirzepatide) is a ...
- Lilly rides wave of weight-loss drug demand, working to expand capacityShares were off about 1% at $696.82 after gaining about 11% in January, making Lilly the eighth largest company in the U.S. by market capit...
- Eli Lilly's new diabetes drug could boost the stock, says SVB SecuritiesSVB Securities believes that the new diabetes drug by Eli Lilly might be able to address patients' obesity and might lead to more significa...
Load More
